

DERMATOLOGY REFERRAL FORM

PATIENT INFORMATION

Patient Name:			SSN:		DOB:	
Address:			City:		State:	Zip:
Home Phone:	Cell:	Email:	Height:	Weight:	Gender:	Male Female

INSURANCE INFORMATION (or attach copy of the cards)

Primary Insurance:	Policy Holder:	Relationship:	Policy #:	Group #:
Secondary Insurance:	Policy Holder:	Relationship:	Policy #:	Group #:

CLINICAL INFORMATION

Primary Diagnosis: Moderate to Severe Plaque Psoriasis Psoriatic Arthritis Hidradenitis Suppurativa Atopic Dermatitis Alopecia Areata Other: _____ **Diagnosis Code(ICD-10):** _____

Date of Diagnosis: _____ TB Test Completed On: _____ BSA: _____ Latex Allergy: Y N

PRESCRIPTION INFORMATION (for IV medication attach a copy of the prescription)

ADBRY™ (tralokinumab-ldm) 150 mg Prefilled Syringe
 Induction: Inject 600 mg (4x150 mg) SubQ
Qty: 4 **Refills:** None
Maintenance:
 Inject 300 mg (2 x150 mg) SubQ every other week
 Inject 300 mg (2 x150 mg) SubQ every 4 weeks
 ADBRY™ Bridge Care™ Program:
 Inject 300 mg (2x 150 mg) SubQ every other week starting on Day 15
Qty: _____ **Refills:** _____

AMJEVITA™ (adalimumab-atto) Prefilled Syringe
 SureClick 40 mg/0.8 mL Prefilled Syringe 20 mg/0.4 mL
 Prefilled Syringe 40 mg/0.8 mL
Maintenance:
 80 mg initial dose, followed by 40 mg every other week starting one week after initial dose.
Qty: _____ **Refills:** _____

CIBINQO™ (abrocitinib) Tablet
 50 mg 100 mg 200 mg
 mg PO once daily
Qty: _____ **Refills:** _____

Cimzia® (certolizumab pegol) Prefilled Syringe
 Induction: Inject 2 x 200 mg/ml SubQ at week 0, 2 and 4
Qty: 6 syringes **Refills:** 0
Maintenance:
 2 x 200 mg SubQ every 4 weeks
 2 x 200 mg SubQ every 2 weeks
 200 mg SubQ every 2 weeks
Qty: 28 days **Refills:** _____

COSENTYX® (secukinumab) 150 mg Sensorready® Pen Kit
 75 mg Prefilled Syringe Kit 150 mg Prefilled Syringe Kit
Induction:
 Inject 300 mg (2 x 150 mg/ml) SubQ week 0, 1, 2, 3, 4
Qty: 10 **Refills:** 0
 Inject 150 mg SubQ week 0, 1, 2, 3, 4
Qty: 5 **Refills:** _____
Maintenance:
 Inject 300 mg SubQ every 4 weeks
 Inject 150 mg SubQ every 4 weeks
Qty: 28 days **Refills:** _____
 Bridge*

DUPIXENT® (dupilumab) Prefilled Syringe Pen
 Induction: Inject 2 x 300 mg (600 mg) SubQ Day 1
Qty: 2 for 14 days **Refills:** None
 Maintenance: Inject 300 mg SubQ every other week
Qty: 2 for 28 days **Refills:** _____

ENBREL® (etanercept)
 Mini Cartridge Prefilled Syringe Autoinjector Vial
 Induction: Inject (50 mg) SubQ twice weekly for three months
Qty: 8 **Refills:** 2
Maintenance: Biosimilar authorized
 50 mg 25 mg
 Once weekly SubQ Twice weekly SubQ
Qty: 8 4 **Refills:** _____

ERIVEDGE™ (vismodegib) capsule 150 mg Once daily PO
 with or without food
Qty: 28 days **Refills:** _____

HUMIRA® (adalimumab)
 Pen Prefilled Syringe
 Citrate Free(CF) Original Formula

Hidradenitis Suppurativa Starter:
 160 mg SubQ day 1/ 80 mg SubQ day 15
 80 mg SubQ day 1/ 80 mg SubQ day 2/ 80 mg SubQ day 15
 Psoriasis Starter:
 80 mg SubQ day 1/ 40 mg SubQ day 8/ 40 mg SubQ day 22
Qty: 1 Pack **Refills:** 0
 Hidradenitis Suppurativa Maintenance:
 40 mg SubQ once weekly, beginning day 29
 80 mg SubQ every other week, beginning day 29
 Psoriasis Maintenance:
 40 mg SubQ every other week
Qty: 28 days **Refills:** _____

INFLECTRA® (infliximab-dyyb) 100 mg vials
 3 mg/kg 5 mg/kg 10 mg/kg
 Induction: Give dose as an IV infusion at 0, 2, and 6 weeks
Qty: _____ **Refills:** 2
 Maintenance: Give dose as an IV infusion every ___ weeks
Qty: _____ **Refills:** 2

ILUMIYA™ (tildrakizumab-asmn) Prefilled Syringe
 Induction: Inject 100 mg/ml SubQ at weeks 0 and 4
Qty: 2 **Refills:** None
 Maintenance: Inject 100 mg/ml SubQ every 12 weeks
Qty: _____ **Refills:** _____

ODOMZO® (sonidegib) capsule 200 mg on an empty stomach,
 at least 1 hr before or 2 hrs after a meal
Qty: 30 **Refills:** _____

OLUMIANT® (baricitinib) tablets
 2 mg PO once daily 4 mg PO once daily
Qty: _____ **Refills:** _____

OTEZLA® (apremilast)
 Titration Pack:
 PO as directed per package instructions
Qty: 1 Pack **Refills:** 0
 Bridge Pack:
 PO as directed per package instructions
Qty: 1 Pack **Refills:** _____

REMICADE® (infliximab) 100 mg vials Biosimilar authorized
 Induction: 5 mg/kg as an IV infusion at 0, 2, and 6 weeks
Qty: 1 dose **Refills:** 2
 Maintenance: 5 mg/kg as an IV infusion every 8 weeks
Qty: _____ **Refills:** _____

RINVOQ® (upadacitinib) extended-release tablets
 15 mg 30 mg
 Once daily PO with or without food
Qty: _____ **Refills:** _____

SIMPONI® (golimumab)
 Prefilled Syringe Autoinjector
 Inject 50 mg SubQ once a month
Qty: 1 **Refills:** _____

SILIQ® (brodalumab) Prefilled Syringe
 Induction: Inject 210 mg SubQ weeks 0 and 1
Qty: 2 **Refills:** 0
 Maintenance: Starting at Week 2 of therapy, inject 210 mg SubQ every two weeks
Qty: 2 **Refills:** _____

SKYZI™ (risankizumab-rzaa)
 Prefilled Syringe Pen
 Inject 150 mg (1 injection) SubQ at Week 0, Week 4
Qty: 2 syringes **Refills:** _____
 Maintenance: Inject 150 mg SubQ every 12 weeks
Qty: _____ **Refills:** _____

STELARA® (ustekinumab)
 45 mg Prefilled Syringe 90 mg Prefilled Syringe
 Induction:
 Inject contents of 1 syringe SubQ on day 0 and day 28
Qty: 1 syringe **Refills:** 1
 Maintenance:
 Inject contents of 1 syringe SubQ every 12 weeks
Qty: 1 syringe **Refills:** _____

SOTYKUT™ (deucravacitinib) 6 mg tablet
 Once daily PO with or without food
Qty: _____ **Refills:** _____

TALTZ® (ixekizumab)
 Citrate Free(CF) Prefilled Syringe
 Autoinjector Prefilled Syringe
 Psoriasis Induction: Inject 160 mg (2 x 80 mg) SubQ at week 0; Inject 80 mg at weeks 2, 4, 6, 8, 10, 12
Qty: 8 **Refills:** 0
 Psoriatic Arthritis Induction: Inject 160 mg (2 x 80 mg) SubQ at week 0
Qty: 2 **Refills:** 0
 Maintenance: 80 mg SubQ every 4 weeks
Qty: 1 **Refills:** _____

TREMFYA® (guselkumab)
 Prefilled Syringe Autoinjector
 Induction: Inject 100 mg SubQ weeks 0 and 4
Qty: 1 **Refills:** 1
 Maintenance: Inject 100 mg SubQ every 8 weeks
Qty: 1 **Refills:** _____

OTHER

STRENGTH:

SIG/DIRECTIONS:

QUANTITY: **REFILLS:**

As required by your state, Prescriber to check "Dispense as written" or handwritten "Brand Medically Necessary" and sign to prevent generic substitution. Dispense as written

PHYSICIAN INFORMATION

Injection Training: Office to Instruct SP to Arrange Teaching

Prescriber Name:		Phone:		Fax:	
Office Contact:			Email:		
Address:			Ship To: <input type="checkbox"/> Patient <input type="checkbox"/> MD Office		
NPI #:		Tax ID#:			
Prescription Signature:				Date:	